HCAT Stock Analysis: Buy, Sell, or Hold?
HCAT - Health Catalyst, Inc Common Stock
$2.15
-0.01 (-0.46%)
▼
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 25, 2026
24d
Get Alerted When HCAT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: HCAT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: HCAT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$4.61
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$2.86
24.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HCAT is currently trading at $2.15, which is considered oversold relative to its 30-day fair value range of $2.23 to $2.44. The stock's valuation (Forward PE: 6.3) is in line with its historical norms (6.9). Remarkably, the market is currently pricing in an annual earnings decline of 3.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, HCAT is in a strong downtrend. The price is currently testing key support at $2.11. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: HCAT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.88 (+79.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HCAT is in a strong downtrend. The price is currently testing key support at $2.11. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: HCAT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.88 (+79.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.23 -
$2.44
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding HCAT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 79.4% below Wall St target ($3.88)
Fair Price Analysis
30-Day Fair Range
$2.23 -
$2.44
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$2.11
Resistance Level
$2.45
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
6.30
Wall Street Target
$3.88
(+79.4%)
Profit Margin
-34.1%
Valuation Discount vs History
-3.0% cheaper
PE vs Historical
6.3 vs 6.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.0%
(market-implied from PE analysis)
1-Year Target
$2.10
(-3%)
2-Year Target
$2.03
(-6%)
3-Year Target
$1.97
(-9%)
3-Yr Target (if PE normalizes)
(PE: 6→7)
$2.16
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 71.3%)
$25.82
(+1096%)
Base:
(SPY PE: 6.3, Growth: 71.3%)
$7.29
(+238%)
Bear:
(PE: 5.4, Growth: 71.3%)
$6.20
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.3 to 6.9
Stabilization Target:
$2.37
(+9.6%)
PE Expansion Potential:
+9.6%
Last updated: January 30, 2026 9:40 PM ET
Data refreshes hourly during market hours. Next update: 10:40 PM
Data refreshes hourly during market hours. Next update: 10:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HCAT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Benjamin Landry
SELL
6175 shares
2025-09-05
Top Rated Health Information Services Stocks
Top-rated stocks in Health Information Services by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VEEV
Veeva Systems Inc Class A |
BUY
32 analysts |
$310 | 54 HOLD |
|
PRVA
Privia Health Group Inc |
STRONG BUY
21 analysts |
$31 | 57 HOLD |
|
GEHC
GE HealthCare Technologi… |
STRONG BUY
21 analysts |
$90 | 60 HOLD |
|
PHR
Phreesia Inc |
STRONG BUY
15 analysts |
$29 | 48 HOLD |
|
HQY
HealthEquity Inc |
STRONG BUY
14 analysts |
$119 | 55 HOLD |
Advanced HCAT Option Strategies
Professional options setups generated by AI based on today's HCAT price and gamma walls.
